肉毒素治疗偏头痛的临床应用与挑战：现状与未来展望

宋 晓琳
青海省湟中区第一人民医院神经内科

摘要


本文综述了肉毒素在治疗慢性偏头痛中的临床应用及其面临的挑战，并展望了未来的研究方向。偏头痛是
一种常见的神经系统疾病，严重影响患者的生活质量。肉毒素最初被用于美容领域，但其通过阻断神经递质释放的
作用机制，使其逐渐在神经科领域崭露头角，尤其在慢性偏头痛的预防性治疗中表现出显著的疗效。临床研究表明，
肉毒素不仅能减少偏头痛的发作频率，还能显著提高患者的生活质量。然而，肉毒素治疗偏头痛仍面临一些挑战，
包括个体疗效差异、不良反应、长期治疗依从性以及治疗费用和可及性问题。不同患者对肉毒素的反应差异较大，
部分患者的治疗效果不显著。同时，治疗费用较高和医疗资源的不平衡也限制了其在全球范围内的推广。针对这些
问题，未来的研究应着重于开发个性化治疗方案、研制新型肉毒素制剂以及探索联合疗法。未来，随着精准医学的
发展，肉毒素的应用有望更加个性化，通过基因特征和临床表现来优化治疗方案。此外，长效制剂和新兴药物递送
系统的研发也将减少患者对频繁注射的依赖。通过持续的机制研究和技术进步，肉毒素在偏头痛治疗中的应用将更
加广泛和高效，为患者提供更持久和安全的治疗方案。

关键词


肉毒素；偏头痛；慢性偏头痛；预防性治疗；神经调节；个性化治疗；个体化治疗

全文:

PDF


参考


[1]Osman Ali MM, Abbasher Hussien Mohamed Ahmed

K, Omer MEA. Prevalence of migraine headaches and their

impact on the academic performance of Sudanese medical

students using ID-Migraine test as a screening tool: A crosssectional study. Brain Behav. 2022;12(5):e2588. doi:10.1002/

brb3.2588

[2]GBD 2016 Headache Collaborators. Global, regional,

and national burden of migraine and tension-type headache,

1990-2016: a systematic analysis for the Global Burden

of Disease Study 2016 [published correction appears in

Lancet Neurol. 2021 Dec;20(12):e7. doi: 10.1016/S1474-

4422(21)00380-X]. Lancet Neurol. 2018;17(11):954-976.

doi:10.1016/S1474-4422(18)30322-3

[3]Natoli JL, Manack A, Dean B, et al. Global prevalence

of chronic migraine: a systematic review. Cephalalgia.

2010;30(5):599-609. doi:10.1111/j.1468-2982.2009.01941.x

[4]Manack AN, Buse DC, Lipton RB. Chronic

migraine: epidemiology and disease burden. Curr Pain

Headache Rep. 2011;15(1):70-78. doi:10.1007/s11916-

010-0157-z

[5]Stovner LJ, Hagen K, Linde M, Steiner TJ. The

global prevalence of headache: an update, with analysis of the

influences of methodological factors on prevalence estimates.

J Headache Pain. 2022;23(1):34. Published 2022 Apr 12.

doi:10.1186/s10194-022-01402-2

[6]Aurora SK, Winner P, Freeman MC, et al.

OnabotulinumtoxinA for treatment of chronic migraine:

pooled analyses of the 56-week PREEMPT clinical program.

Headache. 2011;51(9):1358-1373. doi:10.1111/j.1526-

4610.2011.01990.x

[7]Jackson JL, Kuriyama A, Hayashino Y. Botulinum

toxin A for prophylactic treatment of migraine and

tension headaches in adults: a meta-analysis. JAMA.

2012;307(16):1736-1745. doi:10.1001/jama.2012.505

[8]Herd CP, Tomlinson CL, Rick C, et al. Cochrane

systematic review and meta-analysis of botulinum toxin for

the prevention of migraine. BMJ Open. 2019;9(7):e027953.

Published 2019 Jul 16. doi:10.1136/bmjopen-2018-027953

[9]Ahmed F, Gaul C, García-Moncó JC, Sommer K,

Martelletti P; REPOSE Principal Investigators. An open-label

prospective study of the real-life use of onabotulinumtoxinA

for the treatment of chronic migraine: the REPOSE study.

J Headache Pain. 2019;20(1):26. Published 2019 Mar 7.

doi:10.1186/s10194-019-0976-1

[10]Negro A, Curto M, Lionetto L, Martelletti P. A two

years open-label prospective study of OnabotulinumtoxinA

195 U in medication overuse headache: a real-world

experience. J Headache Pain. 2015;17:1. doi:10.1186/

s10194-016-0591-3

[11]Escher CM, Paracka L, Dressler D, Kollewe K.

Botulinum toxin in the management of chronic migraine:

clinical evidence and experience. Ther Adv Neurol Disord.

2017;10(2):127-135. doi:10.1177/1756285616677005

[12]Kumar R, Dhaliwal HP, Kukreja RV, Singh BR.

The Botulinum Toxin as a Therapeutic Agent: Molecular

Structure and Mechanism of Action in Motor and Sensory

Systems. Semin Neurol. 2016;36(1):10-19. doi:10.1055/

s-0035-1571215

[13]Caleo M, Spinelli M, Colosimo F, et al. Transynaptic

Action of Botulinum Neurotoxin Type A at Central

Cholinergic Boutons. J Neurosci. 2018;38(48):10329-10337.

doi:10.1523/JNEUROSCI.0294-18.2018

[14]Matak I, Riederer P, Lacković Z. Botulinum

toxin's axonal transport from periphery to the spinal cord.

Neurochem Int. 2012;61(2):236-239. doi:10.1016/

j.neuint.2012.05.001

[15]Aurora SK, Dodick DW, Turkel CC, et al.

OnabotulinumtoxinA for treatment of chronic migraine:

results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 1 trial. Cephalalgia.

2010;30(7):793-803. doi:10.1177/0333102410364676

[16]Diener HC, Dodick DW, Aurora SK, et al.

OnabotulinumtoxinA for treatment of chronic migraine:

results from the double-blind, randomized, placebocontrolled phase of the PREEMPT 2 trial. Cephalalgia.

2010;30(7):804-814. doi:10.1177/0333102410364677

[17]Frampton JE, Silberstein S. OnabotulinumtoxinA:

A Review in the Prevention of Chronic Migraine [published

correction appears in Drugs. 2018 Apr;78(6):715. doi:

10.1007/s40265-018-0906-6]. Drugs. 2018;78(5):589-600.

doi:10.1007/s40265-018-0894-6

[18]Rothrock JF, Bloudek LM, Houle TT, AndressRothrock D, Varon SF. Real-world economic impact of

onabotulinumtoxinA in patients with chronic migraine.

Headache. 2014;54(10):1565-1573. doi:10.1111/head.12456

[19]Corbelli I, Verzina A, Leone De Magistris I, et

al. Sustained Efficacy, Safety and High Adherence Rate of

Onabotulinum Toxin Type A in Chronic Migraine Patients:

A Multicentric Prospective Real-Life Study. Toxins (Basel).

2022;15(1):34. Published 2022 Dec 31. doi:10.3390/

toxins15010034

[20]Rempel L, Malik RN, Shackleton C, CalderónJuárez M, Sachdeva R, Krassioukov AV. From Toxin to

Treatment: A Narrative Review on the Use of Botulinum

Toxin for Autonomic Dysfunction. Toxins (Basel).

2024;16(2):96. Published 2024 Feb 10. doi:10.3390/

toxins16020096

[21]Simpson DM, Hallett M, Ashman EJ, et al. Practice

guideline update summary: Botulinum neurotoxin for the

treatment of blepharospasm, cervical dystonia, adult spasticity,

and headache: Report of the Guideline Development

Subcommittee of the American Academy of Neurology.

Neurology. 2016;86(19):1818-1826. doi:10.1212/

WNL.0000000000002560

[22]Blumenfeld A, Silberstein SD, Dodick DW,

Aurora SK, Turkel CC, Binder WJ. Method of injection

of onabotulinumtoxinA for chronic migraine: a safe, welltolerated, and effective treatment paradigm based on the

PREEMPT clinical program. Headache. 2010;50(9):1406-

1418. doi:10.1111/j.1526-4610.2010.01766.x

[23]Lipton RB, Rosen NL, Ailani J, DeGryse RE,

Gillard PJ, Varon SF. OnabotulinumtoxinA improves quality

of life and reduces impact of chronic migraine over one year

of treatment: Pooled results from the PREEMPT randomized

clinical trial program. Cephalalgia. 2016;36(9):899-908.

doi:10.1177/0333102416652092

[24]Silberstein SD, Blumenfeld AM, Cady RK,

et al. OnabotulinumtoxinA for treatment of chronic

migraine: PREEMPT 24-week pooled subgroup analysis

of patients who had acute headache medication overuse at

baseline. J Neurol Sci. 2013;331(1-2):48-56. doi:10.1016/

j.jns.2013.05.003

[25]Winsvold BS, Nelson CP, Malik R, et al. Genetic

analysis for a shared biological basis between migraine and

coronary artery disease. Neurol Genet. 2015;1(1):e10.

Published 2015 Jul 2. doi:10.1212/NXG.0000000000000010

[26]Gormley P, Anttila V, Winsvold BS, et al.

Corrigendum: Meta-analysis of 375,000 individuals

identifies 38 susceptibility loci for migraine. Nat Genet.

2016;48(10):1296. doi:10.1038/ng1016-1296c

[27]Moreno-Mayordomo R, Ruiz M, Pascual J, et al.

CALCA and TRPV1 genes polymorphisms are related to a

good outcome in female chronic migraine patients treated

with OnabotulinumtoxinA. J Headache Pain. 2019;20(1):39.

Published 2019 Apr 23. doi:10.1186/s10194-019-0989-9

[28]Bendtsen L, Sacco S, Ashina M, et al. Guideline

on the use of onabotulinumtoxinA in chronic migraine: a

consensus statement from the European Headache Federation.

J Headache Pain. 2018;19(1):91. Published 2018 Sep 26.

doi:10.1186/s10194-018-0921-8

[29]Stark C, Stark R, Limberg N, et al. Real-world

effectiveness of onabotulinumtoxinA treatment for the

prevention of headaches in adults with chronic migraine

in Australia: a retrospective study. J Headache Pain.

2019;20(1):81. Published 2019 Jul 15. doi:10.1186/s10194-

019-1030-z

[30]Wang L, Ringelberg CS, Singh BR. Dramatic

neurological and biological effects by botulinum neurotoxin

type A on SH-SY5Y neuroblastoma cells, beyond the

blockade of neurotransmitter release. BMC Pharmacol

Toxicol. 2020;21(1):66. Published 2020 Sep 5. doi:10.1186/

s40360-020-00443-0

[31]Egeo G, Fofi L, Barbanti P. Botulinum Neurotoxin

for the Treatment of Neuropathic Pain. Front Neurol.

2020;11:716. Published 2020 Aug 11. doi:10.3389/

fneur.2020.00716

[32]Sandrini G, De Icco R, Tassorelli C, Smania N,

Tamburin S. Botulinum neurotoxin type A for the treatment

of pain: not just in migraine and trigeminal neuralgia. J

Headache Pain. 2017;18(1):38. doi:10.1186/s10194-017-

0744-z

[33]Baraldi C, Lo Castro F, Ornello R, Sacco S, Pani

L, Guerzoni S. OnabotulinumtoxinA: Still the Present for

Chronic Migraine. Toxins (Basel). 2023;15(1):59. Published

2023 Jan 10. doi:10.3390/toxins15010059

[34]Frampton JE. Correction to: OnabotulinumtoxinA

in Chronic Migraine: A Profile of Its Use. CNS Drugs.

2021;35(6):701. doi:10.1007/s40263-021-00828-7


Refbacks

  • 当前没有refback。